Clinical Policy: Linvoseltamab-gcpt (Lynozyfic)
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.743 alerts
Get alerted when Policy CP.PHAR.743 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, dosing limits, prior authorization and continuation requirements for Linvoseltamab-gcpt (Lynozyfic) for commercial, HIM and Medicaid lines of business. Includes excluded indications, dosing/administration, contraindications/boxed warnings, therapeutic alternatives, and coding implications.
Effective date updated to 10.01.25.
HCPCS code J9999 added; J3590 and C9399 removed.
Policy creation and P&T approval dates added (Policy created 07.17.25; P&T approval 08.25).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.